Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9HBZ2
UPID:
ARNT2_HUMAN
Alternative names:
Class E basic helix-loop-helix protein 1
Alternative UPACC:
Q9HBZ2; B4DIS7; O15024; Q8IYC2
Background:
Aryl hydrocarbon receptor nuclear translocator 2, also known as Class E basic helix-loop-helix protein 1, plays a pivotal role in the development of the hypothalamo-pituitary axis, postnatal brain growth, and visual and renal function. It specifically recognizes the xenobiotic response element (XRE), according to PubMed:24022475.
Therapeutic significance:
Linked to Webb-Dattani syndrome, characterized by postnatal microcephaly, multiple pituitary hormone deficiency, and severe visual impairment, this protein's study could lead to novel therapeutic approaches for this syndrome.